Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

Kahan, Z. Gil-Gil, M. Ruiz-Borrego, M. Carrasco, E. Ciruelos, E. Muñoz, M. Bermejo, B. Margeli, M. Antón, A. Casas, M. Csöszi, T. Murillo, L. Morales, S. Calvo, L. Lang, I. Alba, E. Haba-Rodriguez J. de la Ramos, M. Álvarez López, I. Gal-Yam, E. García-Palomo, A. Álvarez, E. González-Santiago, S. Rodríguez, C. A. Servitja, S. Corsaro, M. Rodrigálvarez, G. Zielinski, C. Martín, M. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

Eur. j. cancer

10.1016/j.ejca.2021.07.004 2021

2021